Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAT8881 in Lumbar Radicular Pain
NCT05298306Phase 1Completed
- Sponsor
- Lateral Pharma
- Start
- May 2022
- Primary completion
- May 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in lumbar radiculopathy comparing LAT8881 with Placebo (2 arms). Primary endpoints: Number of Participants With Adverse Events at Day 9 and Change in Baseline Pain With Intravenous LAT8881 at 6 hours. Started May 2022; status: completed.
02
Drugs
LAT8881
03
Conditions
lumbar radiculopathy
Beyond the preview
Go deeper on NCT05298306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05298306.